

Symptom Control & Quality of Life Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
..... Norah Lynn Henry, MD, PhD

Time/Location

Friday, April 8, 2022 7:30 - 9:30 am
Room: Columbia A, Level 3

Agenda

Symposium: Patient-Reported Outcomes and Toxicity Evaluation

Plenary speaker: Gita Thanarajasingam, MD

Panel discussion

Active Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating The Effect Of Immune-Enhancing Nutrition On Radical Cystectomy Outcomes" - Dr.Hamilton-Reeves. Activated 2/21/19.

S1614, "A Phase III Randomized Trial Of Prophylactic Antiviral Therapy In Patients With Current Or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy For Solid Tumors." Drs. Hwang, Lok, and Ghering, et al. Activated 2/21/19, re-activated 7/1/21.

S2013, "Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective Observational Study" – Drs. Gunturu, Hershman, and Kuderer. Activated 8/16/21

Other Concepts in Development

S2205, "STOP CIPN: Randomized trial of Limb Cryocompression versus Continuous Compression versus Low Cyclic Compression for the Prevention of Taxane-Induced peripheral Neuropathy." Dr. Accordino

S2010, "Improving Endocrine Therapy Persistence in Young Women with Breast Cancer using Active Symptom Monitoring." Dr. Henry

Closed Studies

S1714, "A Prospective Observational Cohort Study To Develop A Predictive Model Of Taxane-Induced Peripheral Neuropathy In Cancer Patients"- Drs. Trivedi, Hershman, Brannagan, et al. Activated 3/1/19.

S0702, "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak and Dr. Gralow M.D. Activated 12/15/2008. Closed to Accrual 06/01/19.

S1200, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 3/27/12. Closed: 2/15/17.

Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What has SCQOL contributed to the literature recently?
4. What other updates should we know about

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

Symptom Control & Quality of Life Committee

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Palliative Care and End of Life

S1820, "A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)." Drs. Sun, Thomson, Crane, et al. Activated: 12/9/20.

Prevention and Epidemiology

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices On Incorporating Chemoprevention Into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

NCTN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1600	S1614	S1714	S2013	A221505
Ascension Providence Hospitals - Southfield	-	-	-	1	-
Ascension Via Christi Hospitals Wichita	-	-	1	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	3
Cancer Research Consortium of West Michigan NCORP	-	-	146	-	-
Cancer Research for the Ozarks NCORP	-	-	10	1	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	9	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	6	-	-
City of Hope Comprehensive Cancer Center	2	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	27	-	-
Columbus NCI Community Oncology Research Program	-	-	-	1	-
CommonSpirit Health Research Institute	-	-	71	1	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-
Desert Regional Medical Center	-	-	3	-	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	18	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	10	-	-
Gulf South Minority Underserved NCORP	1	-	26	-	1
Hawaii Minority Underserved NCORP	-	-	70	-	-
Heartland Cancer Research NCORP	-	-	38	10	-
Henry Ford Hospital	7	-	-	-	-
Instituto Nacional De Cancerologia	-	-	10	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	60	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	2	65	-	-
Lahey Hospital and Medical Center	-	-	22	6	-
Loyola University Medical Center	-	-	2	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	30	-	-
Northwell Health NCORP	-	-	-	-	2
Pacific Cancer Research Consortium NCORP	-	-	2	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	278	3	-
The West Clinic - Wolf River	-	-	-	-	6
Tulane University Health Sciences Center	-	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	1
USC Norris Comprehensive Cancer Center LAPS	58	-	-	-	-
University of Arkansas for Medical Sciences	-	-	68	-	-
University of Colorado Cancer Center LAPS	2	-	2	-	16
University of Kansas Cancer Center - MCA Rural MU NCORP	32	-	24	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-
University of Rochester LAPS	6	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	14	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	118	-	1
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-
ALLIANCE	5	-	44	9	-
ECOG-ACRIN	-	-	80	7	-
NRG	1	1	90	9	-
Total	121	3	1,336	57	30

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	A221602	A221702	A221805	EAZ171
Ascension Providence Hospitals - Southfield	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	3	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	1	-
Desert Regional Medical Center	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	1
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-
Loyola University Medical Center	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	2
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-
Northwell Health NCORP	3	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
The West Clinic - Wolf River	-	-	-	-
Tulane University Health Sciences Center	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	1	-
University of Kentucky/Markey Cancer Center	10	-	-	-
University of Rochester LAPS	-	14	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	8	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	32	15	4	3